The safety of novel heart failure therapies, including sacubitril-valsartan and sodium-glucose cotransporter 2 (SGLT2) inhibitors, during pregnancy and the postpartum period remains unknown due to a lack of clinical data. However, these agents are increasingly utilized in the postpartum management of PPCM. Here, SLC5A2 is linked to heart failure.